Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.68
-$0.01-1.41%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.36% | 7.60% | 6.09% | -2.53% | -6.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.43% | -34.41% | -32.84% | -26.53% | -27.26% |
| Operating Income | 42.43% | 34.41% | 32.84% | 26.53% | 27.26% |
| Income Before Tax | 42.52% | 33.62% | 31.11% | 24.68% | 27.42% |
| Income Tax Expenses | -1.73% | -3.08% | 102.94% | -19.73% | -18.78% |
| Earnings from Continuing Operations | 42.50% | 33.60% | 31.07% | 24.68% | 27.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.50% | 33.60% | 31.07% | 24.68% | 27.42% |
| EBIT | 42.43% | 34.41% | 32.84% | 26.53% | 27.26% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 71.14% | 63.00% | 57.99% | 50.88% | 50.51% |
| Normalized Basic EPS | 71.15% | 63.01% | 58.02% | 50.87% | 50.51% |
| EPS Diluted | 71.14% | 63.00% | 57.99% | 50.88% | 50.51% |
| Normalized Diluted EPS | 71.15% | 63.01% | 58.02% | 50.87% | 50.51% |
| Average Basic Shares Outstanding | 147.34% | 115.25% | 74.96% | 56.01% | 49.59% |
| Average Diluted Shares Outstanding | 147.34% | 115.25% | 74.96% | 56.01% | 49.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |